A phase 3 randomized, double-blind, 12-week vehicle-controlled, parallel-group study assessing the efficacy and safety of CD5024 1% cream versus vehicle cream in subjects with papulopustular Rosacea

1% effort 6 subjects

Awarded By

  • Galderma

Contributors

Amount

  • $75,000.00

Start/End

  • March 1, 2012 - September 30, 2013